首页>
外国专利>
IL-8, IL-6, IL-1B AND TET2 AND DNMT3A IN ATHEROSCLEROSIS
IL-8, IL-6, IL-1B AND TET2 AND DNMT3A IN ATHEROSCLEROSIS
展开▼
机译:IL-8、IL-6、IL-1B、TET2和DNMT3A在动脉粥样硬化中的作用
展开▼
页面导航
摘要
著录项
相似文献
摘要
The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.
展开▼